+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a potential new medicine called CDR132L to understand its effects on the structure and function of the heart in people living with heart failure. The study focuses on participants with heart failure who have reduced or mildly reduced ejection fraction and left ventricular hypertrophy. This research is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aiming to assess safety and efficacy in this population. Participants will receive an intravenous infusion of either CDR132L or a placebo once every four weeks for 48 weeks. Alongside this, all participants will continue their individually tailored guideline-directed standard of care therapy for heart failure. The studys main phase covers these 48 weeks of treatment, followed by monitoring adverse events up to week 60. During the approximately 60-week study, participants undergo evaluations including echocardiography and blood tests measuring biomarkers like microRNA-132-3p and NT-proBNP. Researchers will track changes in heart structure and function, adverse events, and safety throughout the study. The primary outcome focuses on changes in normalized microRNA-132-3p levels from baseline to week 24, while secondary outcomes include measures of heart volume and biomarkers, plus adverse event counts.

Age: 40Years - 84YearsAll GendersPhase 2
92 locations
S

Actively Recruiting

Researchers are studying how inflammatory bowel disease IBD activity affects frailty in patients aged 60 years and older. This observational, multicenter, prospective, and longitudinal study aims to understand if frailty and related risks like hospitalization and mortality can be reversed with proactive treatment in frail patients with active IBD. The study also evaluates which frailty index best predicts complications in this population. At the start, four clinical frailty indices will be calculated for each participant, alongside recording clinical variables related to IBD and other health conditions. Patients will be followed through three visits at 3, 6, and 12 months, during which frailty, disease activity, treatment changes, adverse effects, hospitalizations, and mortality will be reassessed to track progress and outcomes. Participants will be involved in these visits where various assessments will be done, including measuring frailty and comorbidities and reviewing their IBD activity and treatments. The main outcomes include assessing the impact of IBD activity on frailty and how frailty affects hospitalization and mortality risk over a 12-month period. The study is led by the Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa and runs until May 2027.

Age: 60Years +All Genders
34 locations
E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
M

Actively Recruiting

Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.

Age: 50Years - 90YearsAll GendersPhase 3
234 locations